Paolo A Ascierto Selected Research

encorafenib

6/2022	STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma.
1/2022	Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128].
1/2021	Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?
1/2021	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS).
11/2020	Systemic Therapy for Melanoma: ASCO Guideline.
10/2020	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K -mutant Solid Tumors.
1/2020	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
3/2019	Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.
1/2019	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
10/2018	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paolo A Ascierto Research Topics

Disease

241	Melanoma (Melanoma, Malignant) 11/2022 - 03/2003
129	Neoplasms (Cancer) 01/2022 - 01/2004
23	Disease Progression 01/2022 - 11/2006
19	Neoplasm Metastasis (Metastasis) 01/2021 - 04/2006
11	Brain Neoplasms (Brain Tumor) 10/2022 - 05/2012
7	Fatigue 01/2022 - 01/2015
6	Colitis 01/2021 - 05/2015
5	Exanthema (Rash) 01/2022 - 03/2013
5	Pneumonia (Pneumonitis) 01/2022 - 08/2015
5	Body Weight (Weight, Body) 10/2019 - 01/2015
5	Neutropenia 01/2017 - 11/2012
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 06/2016
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 03/2014
4	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2018
4	Arthralgia (Joint Pain) 01/2020 - 01/2018
4	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020 - 07/2016
4	Fever (Fevers) 01/2020 - 09/2016
4	Hypertension (High Blood Pressure) 10/2018 - 01/2017
3	COVID-19 01/2022 - 08/2021
3	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 05/2010
3	Skin Neoplasms (Skin Cancer) 01/2022 - 01/2013
3	Microsatellite Instability 01/2022 - 01/2020
3	Nausea 01/2022 - 01/2015
3	Lymphatic Metastasis 11/2020 - 05/2015
3	Colonic Neoplasms (Colon Cancer) 11/2020 - 01/2018
3	Basal Cell Carcinoma (Rodent Ulcer) 12/2018 - 01/2015
3	Myalgia 10/2018 - 08/2015
3	Keratoacanthoma 01/2018 - 03/2014
3	Renal Cell Carcinoma (Grawitz Tumor) 10/2017 - 06/2016
2	Inflammation (Inflammations) 01/2022 - 01/2012
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 06/2016
2	Myasthenia Gravis 01/2021 - 07/2016
2	Uveal melanoma 11/2020 - 01/2017
2	Autoimmune Diseases (Autoimmune Disease) 11/2019 - 07/2011
2	Carcinoma (Carcinomatosis) 01/2019 - 10/2017
2	Breast Neoplasms (Breast Cancer) 01/2019 - 10/2017

Drug/Important Bio-Agent (IBA)

70	IpilimumabIBA 10/2022 - 07/2011
43	NivolumabIBA 10/2022 - 12/2014
42	Immune Checkpoint InhibitorsIBA 05/2022 - 01/2014
42	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 07/2012
41	VemurafenibIBA 10/2021 - 05/2012
39	Biomarkers (Surrogate Marker)IBA 06/2022 - 11/2006
34	pembrolizumabIBA 06/2022 - 02/2015
22	dabrafenibIBA 01/2022 - 05/2012
21	cobimetinibIBA 10/2021 - 07/2012
16	binimetinibIBA 06/2022 - 03/2013
14	LigandsIBA 01/2022 - 07/2012
14	Pharmaceutical PreparationsIBA 02/2021 - 04/2010
13	trametinibIBA 01/2022 - 03/2014
13	Monoclonal AntibodiesIBA 01/2022 - 11/2011
12	encorafenibIBA 06/2022 - 07/2015
12	AntibodiesIBA 12/2020 - 10/2010
11	Dacarbazine (DIC)FDA LinkGeneric 11/2020 - 03/2014
9	Mitogen-Activated Protein KinasesIBA 10/2022 - 11/2015
9	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 10/2021 - 01/2018
8	AntigensIBA 10/2022 - 10/2010
8	Proteins (Proteins, Gene)FDA Link 01/2020 - 08/2005
7	B7-H1 AntigenIBA 01/2022 - 10/2017
7	InterferonsIBA 01/2021 - 10/2008
6	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2004
6	atezolizumabIBA 09/2021 - 01/2017
6	CytokinesIBA 01/2019 - 01/2016
5	Adenosine (Adenocard)FDA LinkGeneric 01/2022 - 01/2019
5	Creatine Kinase (Creatine Phosphokinase)IBA 01/2022 - 03/2013
5	Alanine Transaminase (SGPT)IBA 01/2021 - 04/2015
5	durvalumabIBA 12/2020 - 01/2017
5	Biological ProductsIBA 01/2019 - 10/2008
4	RNA (Ribonucleic Acid)IBA 01/2022 - 11/2018
4	spartalizumabIBA 01/2022 - 10/2020
4	Interleukin-2 (IL2)IBA 01/2021 - 04/2010
4	Programmed Cell Death 1 ReceptorIBA 12/2020 - 11/2018
4	Proto-Oncogene Proteins B-rafIBA 01/2020 - 04/2014
3	EnzymesIBA 01/2022 - 10/2005
3	Circulating Tumor DNAIBA 01/2022 - 11/2018
3	VaccinesIBA 01/2022 - 07/2012
3	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2020 - 03/2003
3	Lipase (Acid Lipase)FDA Link 01/2020 - 11/2012
3	Chimeric Antigen ReceptorsIBA 01/2020 - 11/2016
3	PlatinumIBA 01/2019 - 07/2016
3	HhAntag691IBA 12/2018 - 01/2015
3	Chemokine ReceptorsIBA 11/2017 - 04/2006
3	Interferon-alpha (Interferon Alfa)IBA 08/2014 - 08/2010
3	Arginine (L-Arginine)FDA Link 06/2011 - 10/2005
2	bempegaldesleukinIBA 03/2022 - 10/2020
2	Peptides (Polypeptides)IBA 01/2022 - 07/2016
2	Tyrosine Kinase InhibitorsIBA 01/2021 - 01/2015
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2021 - 08/2016
2	AutoantibodiesIBA 01/2021 - 08/2010
2	CTLA-4 AntigenIBA 12/2020 - 07/2015
2	Phosphotransferases (Kinase)IBA 01/2020 - 01/2016
2	Immune Checkpoint ProteinsIBA 01/2020 - 01/2017

Therapy/Procedure

133	Therapeutics 10/2022 - 01/2006
78	Immunotherapy 10/2022 - 07/2011
24	Drug Therapy (Chemotherapy) 01/2022 - 05/2012
9	Neoadjuvant Therapy 08/2022 - 06/2012
7	Radiotherapy 04/2021 - 05/2012
5	Lymph Node Excision (Lymph Node Dissection) 10/2022 - 01/2018
5	Biological Therapy 08/2014 - 06/2010
4	Retreatment 01/2021 - 01/2014
3	Precision Medicine 01/2021 - 11/2016